DEXILANT can be both affordable and accessible to most patients

Appropriate patients can pay as little as $6.67/month* for a 90-day prescription.

Instant Savings Card

With the DEXILANT Instant Savings Card, patients could pay as little as $20* for their DEXILANT capsule prescriptions and refills.

For EE maintenance, offer a 90-day DEXILANT prescription for appropriate patients. These patients may receive a prescription of DEXILANT capsules for a price similar to that of a generic PPI prescription with the DEXILANT Instant Savings Card.

Fingertip Formulary, July 2018, lansoprazole $18.10, omeprazole $12.31, pantoprazole $6.77, rabeprazole $14.36, commercial insurance, patient pay greater than 30-day supply.

Cost comparisons do not imply comparable safety, efficacy, or FDA-approved indications.

Learn about savings

*Must meet Eligibility Requirements. For commercially insured patients, this savings card covers out-of-pocket expenses greater than $20, up to a maximum benefit of $55 for a 30-day prescription or $165 for a 90-day prescription. For uninsured patients, see Terms & Conditions.

Savings card cannot be used with government programs such as Medicare Part D and Medicaid.

Use the online Patient Access Coverage Tool to search for DEXILANT coverage anytime, anywhere

Search Coverage

Frequently Asked Questions

What is the Patient Access Coverage Tool and how does it work?

The Patient Access Coverage Tool offers formulary coverage data for most ZIP codes. Once a ZIP code is entered, you will see the percentage of insured lives covered in your area, commercial healthcare plans that cover DEXILANT, and Medicare Part D and Medicaid data. Plus, you can compare DEXILANT coverage.

Can my patients use the Patient Access Coverage Tool?

This tool is intended for HCPs, pharmacists, and office staff.

On my mobile device, what is the URL to load the Patient Access Coverage Tool?

What number do I call for general questions about the DEXILANT Instant Savings Card?

Please call 1-866-279-5598.

I am a pharmacist and am having difficulties processing the Instant Savings Card. What should I do?

Please call 1-866-279-5598.

The patient has an Instant Savings Card, but gets his or her prescription via mail order. Can the patient still get the discount?

Yes. Please advise patients that they should visit www.patientrebateonline.com and follow the instructions. If they need further information, direct them to call 1-866-279-5598.

Is the DEXILANT Instant Savings Card a one-time-use card?

No. DEXILANT Instant Savings Cards can be used for multiple prescriptions and refills. If you have any questions, please call us at 1-866-279-5598.

What are patients' eligibility requirements to use the DEXILANT Instant Savings Card?

The DEXILANT Instant Savings Card cannot be used if the patient is a beneficiary of, or any part of the patient's prescription is covered by: (1) any federal, state, or government-funded healthcare program (for example, Medicare, Medicaid, TRICARE), including a state pharmaceutical assistance program (the Federal Employees Health Benefits (FEHB) Program is not a government-funded healthcare program for purposes of this offer), (2) the Medicare Prescription Drug Program (Part D), or if the patient is currently in the coverage gap, or (3) insurance that is paying the entire cost of the prescription.

What are the pharmacist's requirements in submitting the DEXILANT Instant Savings Card for reimbursement?

By submitting this offer for reimbursement to McKesson, you certify that: (1) you have dispensed DEXILANT to an eligible patient in accordance with the Eligibility Requirements of this offer and the accompanying prescription; (2) you have not submitted and will not submit a claim for reimbursement for the portion of the drug covered by this coupon to any payor; (3) your participation in this program is consistent with all applicable laws and any obligations, contractual or otherwise, that you may have as a pharmacy provider; and (4) submission of claims are subject to the LoyaltyScript® program Terms and Conditions posted at www.mckesson.com/mprstnc. For questions about processing, please call 1-866-279-5598.

See Dexilant's Clinical Study Results

IF YOUR PATIENTS CAN'T AFFORD THEIR MEDICATION, TAKEDA
MAY BE ABLE TO HELP

Request Dexilant Samples

Interested in receiving samples of DEXILANT? Submit a request to have samples delivered right to your door.

Important Safety Information

  • DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions, including anaphylaxis, have been reported. Acute interstitial nephritis has been reported with other proton pump inhibitors (PPIs), including lansoprazole. Discontinue DEXILANT if acute interstitial nephritis develops.
  • DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions, including anaphylaxis, have been reported. Acute interstitial nephritis has been reported with other proton pump inhibitors (PPIs), including lansoprazole. Discontinue DEXILANT if acute interstitial nephritis develops.
  • PPIs, including DEXILANT, are contraindicated with rilpivirine-containing products.
  • In adults, symptomatic response with DEXILANT does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing.
  • PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea.
  • Long-term (≥ 1 year) and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the conditions being treated.
  • New onset or worsening of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. The majority of PPI-induced lupus erythematosus cases were CLE. Avoid administration of PPIs for longer than medically indicated. Discontinue DEXILANT and refer the patient to an appropriate specialist for evaluation, if signs or symptoms of CLE or SLE occur. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks.
  • Daily treatment with any acid-suppressing medications over a long period of time (e.g., > 3 years) may lead to malabsorption or a deficiency of cyanocobalamin (Vitamin B-12).
  • Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.
  • Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity which may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop DEXILANT treatment ≥ 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high.
  • Concomitant use of PPIs with methotrexate may elevate and prolong serum concentrations of methotrexate and/or its metabolite, possibly leading to toxicity. With high dose methotrexate administration, consider a temporary withdrawal of DEXILANT.
  • PPI use is associated with an increased risk of fundic gland polyps that increases with long-term use, especially > 1 year. Use the shortest duration of PPI therapy appropriate to the condition being treated.
  • Most commonly reported adverse reactions in adults were diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%).
  • The adverse reaction profile in patients age 12 to 17 years was similar to adults. The most commonly reported adverse reactions in patients age 12 to 17 years (≥ 5%) were headache, abdominal pain, diarrhea, nasopharyngitis, and oropharyngeal pain.
  • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with DEXILANT may reduce antiviral effect. Avoid concomitant use of nelfinavir with DEXILANT. Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with DEXILANT may increase toxicity of the antiretroviral drugs.
  • Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time (PT). Increases in INR and PT may lead to abnormal bleeding and even death.
  • DEXILANT may interfere with absorption of drugs for which gastric pH is important for bioavailability (e.g., digoxin, iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil [MMF], ketoconazole/itraconazole). Use DEXILANT with caution in transplant patients receiving MMF.
  • Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.
  • A hyper-response in gastrin secretion in response to the secretin stimulation test may falsely suggest gastrinoma. Temporarily stop DEXILANT treatment ≥ 30 days before assessing to allow gastrin levels to return to baseline.
  • Avoid concomitant use of DEXILANT with St. John's Wort or rifampin due to decreased exposure of DEXILANT.
  • No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C). The use of DEXILANT is not recommended for these patients.

Indications

DEXILANT (dexlansoprazole) 30 mg and 60 mg delayed-release capsules are indicated in patients ≥ age 12 years for:

  • Healing all grades of erosive esophagitis (EE) for up to 8 weeks
  • Maintaining healing of EE and relief of heartburn for up to 6 months in adults and up to 16 weeks in patients age 12 to 17 years
  • Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for 4 weeks

Use of DEXILANT in patients age 12 to 17 years is supported by evidence from adequate and well-controlled studies of DEXILANT capsules in adults with additional safety, efficacy and pharmacokinetic data in patients age 12 to 17 years.

The safety and effectiveness of DEXILANT have not been established in patients < 12 years of age.

Please see full Prescribing Information, including Medication Guide for DEXILANT.

  1. DEXILANT (dexlansoprazole) prescribing information. Takeda Pharmaceuticals.
  2. Data on file. Takeda Pharmaceuticals.
  3. Metz DC, Howden CW, Perez MC, et al. Aliment Pharmacol Ther. 2009;29:742-754.
  4. Vakily M, Zhang W, Wu J, et al. Curr Med Res Opin. 2009;25:627-638.

Important Safety Information

  • DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions, including anaphylaxis, have been reported. Acute interstitial nephritis has been reported with other proton pump inhibitors (PPIs), including lansoprazole. Discontinue DEXILANT if acute interstitial nephritis develops.
  • DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions, including anaphylaxis, have been reported. Acute interstitial nephritis has been reported with other proton pump inhibitors (PPIs), including lansoprazole. Discontinue DEXILANT if acute interstitial nephritis develops.
  • PPIs, including DEXILANT, are contraindicated with rilpivirine-containing products.
  • In adults, symptomatic response with DEXILANT does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing.
  • PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea.
  • Long-term (≥ 1 year) and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the conditions being treated.
  • New onset or worsening of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. The majority of PPI-induced lupus erythematosus cases were CLE. Avoid administration of PPIs for longer than medically indicated. Discontinue DEXILANT and refer the patient to an appropriate specialist for evaluation, if signs or symptoms of CLE or SLE occur. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks.
  • Daily treatment with any acid-suppressing medications over a long period of time (e.g., > 3 years) may lead to malabsorption or a deficiency of cyanocobalamin (Vitamin B-12).
  • Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.
  • Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity which may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop DEXILANT treatment ≥ 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high.
  • Concomitant use of PPIs with methotrexate may elevate and prolong serum concentrations of methotrexate and/or its metabolite, possibly leading to toxicity. With high dose methotrexate administration, consider a temporary withdrawal of DEXILANT.
  • PPI use is associated with an increased risk of fundic gland polyps that increases with long-term use, especially > 1 year. Use the shortest duration of PPI therapy appropriate to the condition being treated.
  • Most commonly reported adverse reactions in adults were diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%).
  • The adverse reaction profile in patients age 12 to 17 years was similar to adults. The most commonly reported adverse reactions in patients age 12 to 17 years (≥ 5%) were headache, abdominal pain, diarrhea, nasopharyngitis, and oropharyngeal pain.
  • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with DEXILANT may reduce antiviral effect. Avoid concomitant use of nelfinavir with DEXILANT. Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with DEXILANT may increase toxicity of the antiretroviral drugs.
  • Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time (PT). Increases in INR and PT may lead to abnormal bleeding and even death.
  • DEXILANT may interfere with absorption of drugs for which gastric pH is important for bioavailability (e.g., digoxin, iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil [MMF], ketoconazole/itraconazole). Use DEXILANT with caution in transplant patients receiving MMF.
  • Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.
  • A hyper-response in gastrin secretion in response to the secretin stimulation test may falsely suggest gastrinoma. Temporarily stop DEXILANT treatment ≥ 30 days before assessing to allow gastrin levels to return to baseline.
  • Avoid concomitant use of DEXILANT with St. John's Wort or rifampin due to decreased exposure of DEXILANT.
  • No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C). The use of DEXILANT is not recommended for these patients.

Indications

DEXILANT (dexlansoprazole) 30 mg and 60 mg delayed-release capsules are indicated in patients ≥ age 12 years for:

  • Healing all grades of erosive esophagitis (EE) for up to 8 weeks
  • Maintaining healing of EE and relief of heartburn for up to 6 months in adults and up to 16 weeks in patients age 12 to 17 years
  • Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for 4 weeks

Use of DEXILANT in patients age 12 to 17 years is supported by evidence from adequate and well-controlled studies of DEXILANT capsules in adults with additional safety, efficacy and pharmacokinetic data in patients age 12 to 17 years.

The safety and effectiveness of DEXILANT have not been established in patients < 12 years of age.

Please see full Prescribing Information, including Medication Guide for DEXILANT.